Evidence map›Paper›PMID 41341748›Full record

ArticleMolecular therapy. Nucleic acids2025

A novel bispecific siRNA concept: Efficient dual knockdown of

Kaito Ueda, Yuki Yamada, Hiroyuki Tanaka, Tatsuki Sato, Jumpei Sasaki, Sachiko Sakamoto, Kenjiro Minomi, Hiroshi Yamada, Masayuki Sugimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kaito UedaDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Yuki YamadaDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Hiroyuki TanakaDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Tatsuki SatoDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Jumpei SasakiDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Sachiko SakamotoDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Kenjiro MinomiDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Hiroshi YamadaDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.
Masayuki SugimotoDrug Delivery Research and Development Department, Nucleic Acid Medicine Business Division, Corporate Technology Sector, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yes-associated protein (YAP, encoded by

Indexed as

cross-speciesdual targetingGalNAc conjugateliver diseaseMT: Oligonucleotides: Therapies and ApplicationsoligonucleotidesparalogRNA interferencesiRNAtherapies and applicationsYAP/TAZ

Identifiers

PMID41341748
PMCPMC12670904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.